Blood Reviews
Volume 23, Issue 6 , Pages 241-244 , November 2009

Atrial fibrillation and coagulation: Who and when?

References 

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22:983–988
  2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Int Med. 1995;155:469–473
  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly – the framingham study. Arch Int Med. 1987;147:1561–1564
  4. Fitzmaurice DA, Hobbs FDR, Jowett J, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M, Lip GYH, Allan TF. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383–6, doi:10.1136/bmj.39280.660567.55 (published 2 August 2007).
  5. Reid DD, Brett GZ, Hamilton PJS, Keen H, Rose G. Cardiorespiratory disease and diabetes among middle-aged male civil servants. Lancet 1974;i:469–73.
  6. Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and prognosis of electrocardiographic findings in middle aged men. Br Heart J. 1978;40:636–643
  7. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987;i:526–9.
  8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation; analysis of pooled data from five randomised controlled trials. Arch Int Med 1994;154:1449–57.
  9. Lip GYH. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk. Lancet. 1997;349:1565–1566
  10. Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thrombo-embolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175–178
  11. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527–39.
  12. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–11.
  13. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349–355
  14. European Atrial Fibrillation Study group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255–62.
  15. Ezekowitz ND, Bridge SL, James KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412
  16. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke prevention in atrial fibrillation II study. Lancet 1994;343:687–91.
  17. Stroke prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633–8.
  18. Sweeney KG, Pereira Gray D, Steele R, Evans P. Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. BJGP. 1995;45:153–158
  19. Albers GW. Atrial fibrillation and stroke. Arch Int Med. 1994;154:1443–1448
  20. Cage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839–1845
  21. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of haemorrhagic stroke. JAMA. 1998;280:1930–1935
  22. http://www.nice.org.uk/Guidance/CG36.
  23. Go, AS, Hylek, EM, Chang, Y, et al, JAMA 2003;290:2685.
  24. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA. 2002;288:2441–2448
  25. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice DA, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly population with atrial fibrillation (the Birmingham Atrial Fibrillation treatment of the aged study, BAFTA): a randomized controlled trial. Lancet. 2007;370:493–503
  26. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–546
  27. Hylek EM, Singer DE. Risk factors for intracranial haemorrhage in out-patients taking warfarin. Ann Intern Med. 1994;120:897–902
  28. Lancaster T, Mant J, Singer DE. Stroke prevention in atrial fibrillation. BMJ. 1997;314:1563–1564
  29. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etixilate vs enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomised trial. J Thrombosis Haemostasis. 2007;5:2178–2185
  30. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etixilate vs enoxaparin for the prevention of venous thromboembolism after total hip replacement: a randomised double-blind, non-inferiority trial. Lancet. 2007;370:949–956
  31. Friedman RJ, Caprini JA, Comp PC et al. Dabigatran etixilate vs enoxaparin in preventing venous thromboembolism following total knee arthroplasty (the RE-MOBILIZE trial). J Thrombosis Haemostasis 2007;5(suppl1): o-w-051.
  32. Eriksson BI, Borris L, Friedman RJ, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after hip surgery. N Engl J Med. 2008;358:2765–2775

PII: S0268-960X(09)00043-5

doi: 10.1016/j.blre.2009.07.006

Blood Reviews
Volume 23, Issue 6 , Pages 241-244 , November 2009

Article Tools